FDA clearance for blood lead testing system, 9/15
Magellan Diagnostics received FDA 510(k) clearance to market its LeadCare Plus Blood Lead Testing System in the U.S. for the quantification of lead levels in blood.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Multimode microplate reader, 9/15
BioTek released the Synergy Neo2 Multi-Mode Reader, which is designed for speed and ultra-high performance and incorporates BioTek’s patented Hybrid Technology with independent optical paths. Continuously variable bandwidth quadruple monochromators, sensitive high transmission filter-based optics, and up to four photomultiplier tubes provide fast measurements with excellent results, according to a company statement.
qPCR-based library quantitation solution, 9/15
New England Biolabs released the NEBNext Library Quant Kit for Illumina, a qPCR-based solution for accurate next-generation sequencing library quantitation.
Laboratory Essentials course, 9/15
Total Lab Care’s Laboratory Essentials course has been approvedT for 3.5 hours of P.A.C.E. continuing education credits. This Web-based interactive training program comprises 10 individual lessons and reviews CLIA rules and regulations and laboratory operations from preanalytical to postanalytical processes, including laboratory testing requirements (pipetting, safety, equipment operation, etc.).
Clinical expert intelligence system, 9/15
Pacific Knowledge Systems has relaunched in the United States with a suite of solutions based on its patented RippleDown technology, a clinical expert intelligence system that replicates a domain expert’s human decision-making process at scale and with absolute accuracy, according to a company statement.
Stable-labeled internal standards, 9/15
Sigma-Aldrich’s Cerilliant brand has introduced five stable-labeled internal standards of the antifungal agents fluconazole, itraconazole, ketoconazole, posaconazole, and voriconazole at 1.0 mg/mL concentrations. The reference materials offer clinical and diagnostic testing labs, hospitals, and bioanalytical/pharmacokinetics and drug metabolism labs a full selection of internal standards for quantitation of common antifungal drugs in serum or plasma by mass spectrometry–based analytical methods. The deuterium or 13C substitutions of each internal standard were chosen to conserve a minimum (M+3) separation from the unlabeled
HbA1c calibration verification and linearity test kit, 9/15
Maine Standards released its Validate HbA1c calibration verification/linearity test kit. The kit evaluates percentage of glycohemoglobin A1c in a human-whole-blood base matrix. Each kit is prepared using the CLSI recommended “equal delta” method for linearity testing and is liquid and ready to use—add the product from the dropper bottle directly into a sample cup and run as a patient sample in duplicate or triplicate.
Gene deletion/duplication analysis, 9/15
BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti, announced the availability of genetic deletion/duplication analysis. Using array comparative genomic hybridization (aCGH), this test provides timely detection of deletions and/or duplications that may escape detection with standard DNA sequencing tests. The test allows for the detection of deletions and duplications within a given gene, whether within a single exon, encompassing one or more exons, or the entire gene.
CLSI Excellence Awards, 9/15
CLSI’s Excellence Awards are bestowed on volunteers who are dedicated and committed to the organization’s mission and who significantly contribute their services to the development, implementation, and promotion of consensus standards. The winners were nominated by their peers and then selected by the CLSI Awards Committee and announced in July.
CE mark for software, 9/15
Ariosa Diagnostics’ proprietary Forte software received the CE mark—a significant achievement toward the continued expansion of the Harmony Prenatal Test in Europe and worldwide, according to a company statement.